# A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

> **NCT05238883** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **HiFiBiO Therapeutics** · enrollment: 72 (actual)

## Conditions studied

- Gastric Cancer
- Renal Cell Carcinoma
- Melanoma
- Sarcoma
- Testicular Germ Cell Tumor
- Cervical Cancer
- Mesothelioma
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** HFB200301
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05238883
- **Lead sponsor:** HiFiBiO Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-10
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238883, "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05238883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*